QLOSI™ is a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials Affecting more than 128 million people in the…
- Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023 Ponte Vedra, FL, February 21, 2023 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused…
- Presbyopia is the loss of ability to focus on near objects as a result of the natural aging process and affects more than 120 million people in the U.S.…
- Two presentations on the Phase 2b clinical trial show CSF-1 met the primary endpoints and achieved statistically significant and clinically meaningful improvements in distance-corrected near visual acuity (DCNVA) for…
- Phase 3 NEAR-1 and NEAR-2 clinical trials met primary and key secondary endpoints - Presbyopia is the loss of ability to focus on near objects as a result of…
Herzliya, Israel, April 12, 2022 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, today announced…
Herzliya, Israel, April 7, 2022 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, today announced…